Jörg Wischhusen studied biochemistry in Tübingen, Germany. During his thesis on mechanisms of immune escape in glioma (mentored by Michael Weller and Hans-Georg Rammensee) he performed early work in the field of experimental immune checkpoint blockade. In 2005 he was recruited as a junior research group leader to the University of Würzburg where he became a professor in 2013. His group explores whether mechanisms that enable immune tolerance during pregnancy can be targeted or exploited for immunomodulation in cancer or autoimmunity. He is the author >100 peer-reviewed publications, inventor on 16 patent families and scientific founder of the biotech companies CatalYm and Toleris Biotherapeutics. In 2022 he received the Innovation award of the German biotech regions together with his co-worker (and former student) Valentin Bruttel. Jörg is also an active classical pianist holding a concert diploma from the conservatory in Winterthur.